Amicus, GSK and others receive CHMP nods

EMA's CHMP handed down a basket of marketing approval recommendations Friday, including recommendations for Fabry's disease therapy Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD) and gene therapy Strimvelis ( GSK2696273) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

CHMP recommended Galafold as

Read the full 399 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE